RAPP: SEC Form 424B5 filed by Rapport Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for RAPP
Across the 25 sessions after earlier RAPP headlines, the stock closed higher 17 times and lower 8 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RAPP | SPY |
|---|---|---|---|
| Oct 28, 2026 | Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placementand 1 other headline that session | -18.3% | +0.3% |
| Oct 20, 2026 | Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania | +2.7% | +0.3% |
| Oct 15, 2026 | UBS initiated coverage on Rapport Therapeutics with a new price targetand 1 other headline that session | +4.4% | +0.3% |
| Oct 6, 2026 | Guggenheim initiated coverage on Rapport Therapeutics with a new price target | -3.2% | +0.5% |
| Sep 2, 2026 | Rapport Therapeutics to Participate in Upcoming Investor Conferences | +0.3% | +0.4% |
| Aug 24, 2026 | Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program | +2.3% | -0.3% |
Quantisnow market dataNASDAQ
RAPP
Rapport Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for RAPP
Full RAPP profile on Quantisnow Follow RAPP and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time